Jonathan Violin - 08 Sep 2026 Form 3 Insider Report for Korsana Biosciences, Inc. (CYCN)

Reporting relationship: Chief Executive Officer and President Exhibit 24 - Power of Attorney, Director
Issuer ticker: CYCN
Reported as of: 08 Sep 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 10 Sep 2026, 17:36:41 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Vignola, as attorney-in-fact for Jonathan Violin

Key filing fact

Jonathan Violin filed Form 3 for Korsana Biosciences, Inc. (CYCN) on 10 Sep 2026.

Key facts

This page summarizes Jonathan Violin's Form 3 filing for Korsana Biosciences, Inc. (CYCN).
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Sep 2026, 17:36.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730615 Primary reporting owner

Violin Jonathan

Relationship: Chief Executive Officer and President Exhibit 24 - Power of Attorney, Director
Address: C/O KORSANA BIOSCIENCES, INC., 203 CRESCENT STREET, SUITE 503, WALTHAM
Signature: /s/ Mark Vignola, as attorney-in-fact for Jonathan Violin
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 207,400
Date: 08 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYCN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,048,244
Exercise price: $4.15
Footnotes: F1, F3

CYCN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,984,157
Exercise price: $8.06
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer").

Footnote F2

Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Korsana's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Korsana's restricted common stock held at the Effective Time was exchanged for 0.2074 restricted shares of the Issuer's common stock. Of these shares of common stock, 142,588 remain subject to forfeiture restrictions and vest in equal monthly installments through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Footnote F3

Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option vested as to 25% on June 1, 2026 and vests in equal monthly installments thereafter through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Footnote F4

Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option will vest as to 25% on June 18, 2027 and in equal monthly installments thereafter through June 18, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

Chief Executive Officer and President Exhibit 24 - Power of Attorney